Levetiracetam 100mg/mL; IV infusion after dilution. Infuse over 15mins. Partial onset: ≥16yrs: initially 500mg twice daily; may increase at 2-week intervals in increments of 1g/day; max 3g/day ...

Keppra is a brand-name drug that’s prescribed for certain types of seizures. It contains the active ingredient levetiracetam. Keppra may or may not be safe to take during pregnancy and ...

Levetiracetam 500mg, 750mg; ext-rel tabs. Swallow whole. ≥12yrs (≥50kg): initially 1g once daily; may increase at 2-week intervals in increments of 1g/day; max 3g/day. Renal impairment: CrCl ...

Ruth Talbot, Asia Fields, Nicole Santa Cruz and Maya Miller, design by Zisiga Mukulu and Ruth Talbot, illustrations by Matt ...

If they don’t, then we keep them on gabapentin. If they have more, we increase them to Keppra [brand name for levetiracetam] or phenobarbital, stronger seizure drugs.” Gabapentin also helps alleviate ...

It's not wholly new however as some established drugs, namely UCB's Keppra (levetiracetam) and Briviact (brivaracetam), bind to SV2A and inhibit its activity as a way to treat epilepsy.

The firm has now emerged from the patent expiry of its old mainstay, allergy treatment Zyrtec, and the slow post-patent decline of epilepsy drug Keppra. UCB now has three core brands: Cimzia ...

Both Keppra and Briviact are used to treat epilepsy, a market with strong growth potential. This drug market is anticipated to experience substantial growth due to several factors. First ...

Am J Health Syst Pharm. 2009;66(6):541-561. Shorvon et al. [20] conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and tolerability of ...

In a report released today, Xian Deng from UBS maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

The family of an inmate who lay dying alone on a footpath within one day of being released from prison say he was not given his epilepsy medication during the five weeks he spent in custody.

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00.